Abstract Background: Previous exposure to human common cold coronaviruses (hCCCoVs) has been shown to affect immune responses to SARS-CoV-2. Since most humans have been infected with different hCCoVs throughout their lives, determining exactly how previous immunity to hCCoVs affects anti-SARS-CoV-2 responses, especially to the Spike (S) protein and its receptor-binding domain (RBD), has proven difficult. We, therefore, used a mouse model to investigate how exposure to different coronavirus S alters the immune response to SARS-CoV-2 S vaccination. Methods: C57BL/6 mice were vaccinated intramuscularly with 30 μg of full-length S from several coronaviruses: hCCCoVs, SARS-CoV, or SARS-CoV-2. All mice were then vaccinated with SARS-CoV-2 full-length S 33 days later. Sera from all mice were collected at multiple timepoints after vaccinations and analyzed by ELISA and microneutralization assays. Results: Initial SARS-CoV S vaccination, surprisingly, led to significantly higher levels of anti-RBD IgG antibodies compared to SARS-CoV-2 vaccination. Boosting with SARS-CoV-2 S increased SARS-CoV-2 S IgG and IgM levels, regardless of previous vaccination, but increased RBD IgG responses more in SARS-CoV and SARS-CoV-2 S mice and only previous SARS-CoV S vaccination increased in anti-RBD IgM levels. Microneutralization assay results of each timepoint significantly correlated with combined anti-RBD IgG and IgM levels. Conclusions: SARS-CoV S vaccination leads to more robust anti-SARS-CoV-2 RBD antibody levels in both naïve and SARS-CoV-2 S-vaccinated mice than other coronaviruses studied. Further investigation will help explore which aspects of this SARS-CoV S vaccination could lead to an increased RBD-focused immune response. David C. Brice was supported through The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists.
Read full abstract